AI주식인사이트AI Stock Insight
B

대웅

003090KOSPI

59.5 / 100

Reference Date: 2026-09-08

Financial Score34.0 / 40
News Sentiment12.5 / 25
Momentum6.0 / 20
Disclosure7.0 / 15
AI Analysis: PER is significantly undervalued vs. peers and PBR is significantly undervalued vs. peers is also solid. Declined 5.6% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Dae Woong Co., Ltd., a global healthcare group holding company, reported consolidated sales of 2.684 trillion KRW in 2025, a 6.8% increase from the previous year, though operating profit declined 7.1% to 2.618 billion KRW. Its subsidiary Dae Woong Pharm achieved 13.91 trillion KRW in sales and 2.036 billion KRW in operating profit in 2025, driven by growth in key products like Nabohta and Pexuclo, as well as investments in R&D and digital healthcare initiatives.

Number of Employees

413people

Average Salary

69.2M KRW

Score Calculation Basis

Detailed Financial Score

PER
4.32Industry Average 15.008.0Point

Half of industry avg (excellent)

PBR
0.56Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE
13.94Industry Average 8.005.5Point

1.7x industry avg (good)

Debt Ratio
39.33Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20257.0 / 10 points
Revenue Growth Rate
2.0 / 3

Avg ▲6.8% (2-year basis)

Operating Profit Growth Rate
2.5 / 3

Avg ▲18.5% (2-year basis)

ROE Trend
2.5 / 4

Avg ROE 10.9% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (8%, downtrend)

Current 16,930Won52-week high 29,35052-week low 15,850
1-month return2.0Point

1m -5.63% (slight drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

3 totalPositive 0Neutral 2Negative 1
  • Neutral타인에대한채무보증결정(자회사의 주요경영사항)2026-09-04
  • Negative소송등의제기ㆍ신청(일정금액이상의청구)(자회사의 주요경영사항)2026-09-02
  • Neutral반기보고서 (2026.06)2026-08-14